Table 1.
Characteristics (number [%]) of the population under study – dose 1 cohort
| Characteristic | All eligible for dose 1 analysis | Vaccination status during dose 1 follow-up | ||||
|---|---|---|---|---|---|---|
| Unvaccinated | ChAdOx1 | BNT162b2 | mRNA-1273 | |||
| Total | All | 45,673,965 | 8,424,120 (18.44%) | 19,317,985 (42.30%) | 16,846,995 (36.89%) | 1,084,865 (2.38%) |
| Sex | Male | 22,607,555 (49.5%) | 4,718,635 (56.01%) | 9,421,000 (48.77%) | 7,875,835 (46.75%) | 592,085 (54.58%) |
| Female | 23,066,410 (50.5%) | 3,705,480 (43.99%) | 9,896,985 (51.23%) | 8,971,165 (53.25%) | 492,780 (45.42%) | |
| Age (years) | 18–29 | 8,847,920 (19.4%) | 2,776,200 (32.96%) | 1,021,805 (5.29%) | 4,572,045 (27.14%) | 477,870 (44.05%) |
| 30–39 | 8,484,105 (18.6%) | 2,450,210 (29.09%) | 1,630,695 (8.44%) | 4,020,215 (23.86%) | 382,985 (35.30%) | |
| 40–49 | 7,540,600 (16.5%) | 1,430,495 (16.98%) | 4,322,935 (22.38%) | 1,585,815 (9.41%) | 201,355 (18.56%) | |
| 50–59 | 7,700,005 (16.9%) | 865,605 (10.28%) | 5,284,090 (27.35%) | 1,534,230 (9.11%) | 16,080 (1.48%) | |
| 60–69 | 5,871,400 (12.9%) | 474,340 (5.63%) | 3,762,510 (19.48%) | 1,629,755 (9.67%) | 4795 (0.44%) | |
| 70–79 | 4,594,010 (10.1%) | 248,830 (2.95%) | 2,529,425 (13.09%) | 1,814,400 (10.77%) | 1355 (0.12%) | |
| 80–89 | 2,157,220 (4.72%) | 130,310 (1.55%) | 575,940 (2.98%) | 1,450,595 (8.61%) | 375 (0.03%) | |
| 90+ | 478,710 (1.05%) | 48,130 (0.57%) | 190,590 (0.99%) | 239,940 (1.42%) | 50 (0.00%) | |
| Ethnic group | Asian | 3,740,455 (8.19%) | 855,560 (10.16%) | 1,316,815 (6.82%) | 1,488,545 (8.84%) | 79,535 (7.33%) |
| Black | 1,675,070 (3.67%) | 651,935 (7.74%) | 489,720 (2.54%) | 497,755 (2.95%) | 35,660 (3.29%) | |
| Mixed | 717,695 (1.57%) | 249,425 (2.96%) | 196,505 (1.02%) | 248,795 (1.48%) | 22,970 (2.12%) | |
| Other | 1,448,035 (3.17%) | 626,600 (7.44%) | 361,545 (1.87%) | 422,270 (2.51%) | 37,620 (3.47%) | |
| White | 36479155 (79.9%) | 5285020 (62.74%) | 16,524,935 (85.54%) | 13,798,605 (81.91%) | 870,595 (80.25%) | |
| Unknown/Missing | 1,613,555 (3.53%) | 755,580 (8.97%) | 428,465 (2.22%) | 391,025 (2.32%) | 38,485 (3.55%) | |
| Index of multiple deprivation (1 most, 10 leas deprived) | 1–2 | 8,651,540 (18.9%) | 2,294,285 (27.23%) | 3,253,630 (16.84%) | 2,926,715 (17.37%) | 176,910 (16.31%) |
| 3–4 | 9,015,905 (19.7%) | 2,090,015 (24.81%) | 3,535,865 (18.30%) | 3,184,335 (18.90%) | 205,690 (18.96%) | |
| 5–6 | 8,815,855 (19.3%) | 1,554,155 (18.45%) | 3,803,565 (19.69%) | 3,258,740 (19.34%) | 199,395 (18.38%) | |
| 7–8 | 8,580,765 (18.8%) | 1,198,325 (14.22%) | 3,948,195 (20.44%) | 3,240,875 (19.24%) | 193,370 (17.82%) | |
| 9–10 | 8,300,280 (18.2%) | 922,005 (10.94%) | 4,037,545 (20.90%) | 3,143,075 (18.66%) | 197,655 (18.22%) | |
| Missing | 2,309,620 (5.06%) | 365,330 (4.34%) | 739,185 (3.83%) | 1,093,260 (6.49%) | 111,845 (10.31%) | |
| Smoking status | Current | 7,788,670 (17.1%) | 2,216,230 (26.31%) | 3,000,925 (15.53%) | 2,385,020 (14.16%) | 186,495 (17.19%) |
| Former | 10,414,755 (22.8%) | 1,267,720 (15.05%) | 5,255,825 (27.21%) | 3,728,875 (22.13%) | 162,335 (14.96%) | |
| Never | 25,332,265 (55.5%) | 4,158,860 (49.37%) | 10,754,915 (55.67%) | 9,790,240 (58.11%) | 628,250 (57.91%) | |
| Missing | 2,138,275 (4.68%) | 781,300 (9.27%) | 306,325 (1.59%) | 942,865 (5.60%) | 107,785 (9.94%) | |
| Medical history | AMI | 1,161,760 (2.54%) | 85,295 (1.01%) | 567,515 (2.94%) | 507,980 (3.02%) | 970 (0.09%) |
| Diabetes | 3,907,740 (8.56%) | 301,965 (3.58%) | 1,999,260 (10.35%) | 1,598,265 (9.49%) | 8250 (0.76%) | |
| Depression | 9,426,550 (20.6%) | 1,325,580 (15.74%) | 4,602,700 (23.83%) | 3,328,455 (19.76%) | 169,815 (15.65%) | |
| Obesity | 4,384,350 (9.60%) | 402,695 (4.78%) | 2,298,955 (11.90%) | 1,639,185 (9.73%) | 43,515 (4.01%) | |
| Cancer | 6,465,720 (14.2%) | 576,160 (6.84%) | 3,122,945 (16.17%) | 2,664,130 (15.81%) | 102,485 (9.45%) | |
| COPD | 1,549,765 (3.39%) | 116,345 (1.38%) | 798,160 (4.13%) | 633,205 (3.76%) | 2055 (0.19%) | |
| Liver disease | 225,630 (0.49%) | 32,055 (0.38%) | 117,550 (0.61%) | 75,170 (0.45%) | 855 (0.08%) | |
| CKD | 2,867,785 (6.28%) | 214,160 (2.54%) | 1,346,545 (6.97%) | 1301,275 (7.72%) | 5805 (0.54%) | |
| Dementia | 510,600 (1.12%) | 49,230 (0.58%) | 268,085 (1.39%) | 193,075 (1.15%) | 210 (0.02%) | |
| All stroke | 835,305 (1.83%) | 67,115 (0.80%) | 423,070 (2.19%) | 344,140 (2.04%) | 980 (0.09%) | |
| All VTE | 642,035 (1.41%) | 66,330 (0.79%) | 329,515 (1.71%) | 244,180 (1.45%) | 2010 (0.19%) | |
| Thrombophilia | 43,440 (0.10%) | 5130 (0.06%) | 20,795 (0.11%) | 17,020 (0.10%) | 495 (0.05%) | |
| Major surgery in the last year | 3,438,335 (9.23%) | 423,490 (5.03%) | 732,470 (5.17%) | 1,602,550 (9.51%) | 53,680 (4.95%) | |
| No. of unique diseases in the last year | 0 | 36,130,080 (79.1%) | 7,478,345 (88.77%) | 14,694,520 (76.07%) | 13,005,675 (77.20%) | 951,540 (87.71%) |
| 1–5 | 9,412,710 (20.6%) | 933,460 (11.08%) | 4,554,595 (23.58%) | 3,791,520 (22.51%) | 133,135 (12.27%) | |
| 6+ | 131,170 (0.29%) | 12,300 (0.15%) | 68,875 (0.36%) | 49,805 (0.30%) | 190 (0.02%) | |
| Region | Northwest | 5,658,370 (12.4%) | 1,006,965 (11.95%) | 2,423,155 (12.54%) | 2,106,490 (12.50%) | 121,760 (11.22%) |
| Southeast | 6,574,915 (14.4%) | 1,007,385 (11.96%) | 3,002,770 (15.54%) | 2,378,170 (14.12%) | 186,590 (17.20%) | |
| London | 7,210,945 (15.8%) | 2,248,485 (26.69%) | 2,356,510 (12.20%) | 2,429,115 (14.42%) | 176,835 (16.30%) | |
| East of England | 4,040,560 (8.85%) | 663,225 (7.87%) | 1,830,055 (9.47%) | 1,455,715 (8.64%) | 91,565 (8.44%) | |
| Southwest | 3,574,255 (7.83%) | 463,450 (5.50%) | 1,616,385 (8.37%) | 1,397,850 (8.30%) | 96,570 (8.90%) | |
| Yorkshire/Humber | 5,096,465 (11.2%) | 714,715 (8.48%) | 1,900,555 (9.84%) | 1,517,425 (9.01%) | 113,245 (10.44%) | |
| East Midlands | 4,245,940 (9.30%) | 484,935 (5.76%) | 1,434,740 (7.43%) | 1,192,780 (7.08%) | 13,055 (1.20%) | |
| West Midlands | 3,125,510 (6.84%) | 821,550 (9.75%) | 1,942,855 (10.06%) | 1,627,415 (9.66%) | 70,815 (6.53%) | |
| Northeast | 4,462,635 (9.77%) | 254,925 (3.03%) | 761,420 (3.94%) | 628,785 (3.73%) | 39,240 (3.62%) | |
| Missing | 1,684,370 (3.69%) | 758,495 (9.00%) | 2,049,535 (10.61%) | 2,113,255 (12.54%) | 175,180 (16.15%) | |
| Prior COVID-19 at index date | 2,496,910 (5.5%) | 119,535 (1.42%) | 464,180 (2.40%)) | 488,985 (2.90%)) | 29,215 (2.69%) | |
| Medications taken in the last 3 months | Antiplatelet | 119,325 (1.42%) | 142,340 (1.00%) | 1,215,145 (6.29%) | 1,108,890 (6.58%) | 2445 (0.23%) |
| Blood pressure lowering | 8,390,090 (18.4%) | 367,775 (4.37%) | 4,520,250 (23.40%) | 3,486,990 (20.70%) | 15,075 (1.39%) | |
| Lipid lowering | 6,651,900 (14.6%) | 241,945 (2.87%) | 3,552,420 (18.39%) | 2,851,365 (16.93%) | 6170 (0.57%) | |
| Anticoagulant | 1,300,380 (2.85%) | 64,025 (0.76%) | 613,405 (3.18%) | 622,200 (3.69%) | 750 (0.07%) | |
| COCP | 612,760 (1.34%) | 67,420 (0.80%) | 143,415 (0.74%) | 368,470 (2.19%) | 33,455 (3.08%) | |
| HRT | 530,515 (1.16%) | 20,320 (0.24%) | 350,180 (1.81%) | 156,765 (0.93%) | 3250 (0.30%) | |
| Clinically vulnerable | Neither | 35,461,085 (77.6%) | 7,547,780 (89.60%) | 14,122,735 (73.11%) | 12,731,880 (75.57%)) | 1,058,690 (97.59%) |
| Vulnerable | 8,084,085 (17.7%) | 711,505 (8.45%) | 4,094,310 (21.19%) | 3,255,215 (19.32%) | 23,055 (2.13%) | |
| Extremely vulnerable | 2,128,795 (4.66%) | 164,830 (1.96%) | 1,100,945 (5.70%) | 859,900 (5.10%) | 3120 (0.29%) | |
CKD Chronic Kidney Disease, COCP Combined Oral Contraceptive Pill, COPD Chronic Obstructive Pulmonary Disease, HRT Hormone Replacement Therapy